About Chroma Medicine
Chroma Medicine is a company based in Cambridge (United States) founded in 2020.. Chroma Medicine has raised $135 million across 3 funding rounds from investors including ARE, T. Rowe Price and Janus Henderson Investors. The company has 122 employees as of December 31, 2023. Chroma Medicine has completed 1 acquisition, including Epsilen Bio. Chroma Medicine offers products and services including Epigenetic Editors, DLVR Particles, and CRMA-1001. Chroma Medicine operates in a competitive market with competitors including FOXO Technologies, Reaction Biology, Chronomics, Epsilen Bio and Epigenica, among others.
- Headquarter Cambridge, United States
- Employees 122 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$135 M (USD)
in 3 rounds
-
Latest Funding Round
$135 M (USD), Series B
Feb 08, 2023
-
Investors
ARE
& 17 more
-
Employee Count
122
as on Dec 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Chroma Medicine
Chroma Medicine offers a comprehensive portfolio of products and services, including Epigenetic Editors, DLVR Particles, and CRMA-1001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables one-time cures by regulating genes without DNA changes.
Facilitates efficient, cell-specific delivery of macromolecules for editing.
Targets chronic hepatitis B for deep, durable gene silencing.
Unlock access to complete
Unlock access to complete
Funding Insights of Chroma Medicine
Chroma Medicine has successfully raised a total of $135M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $135.0M
- First Round First Round
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2023 | Amount | Series B - Chroma Medicine | Valuation | Google Ventures | |
| Nov, 2021 | Amount | Series A - Chroma Medicine | Valuation | Cormorant-asset | |
| Jun, 2020 | Amount | Seed - Chroma Medicine | Valuation | Newpath Partners , Atlas Venture |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Chroma Medicine
Chroma Medicine has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, T. Rowe Price and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Private equity and debt investments are managed across multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Chroma Medicine
Chroma Medicine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epsilen Bio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Epigenetic gene silencing technologies are developed for disease treatments.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Chroma Medicine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Chroma Medicine Comparisons
Competitors of Chroma Medicine
Chroma Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as FOXO Technologies, Reaction Biology, Chronomics, Epsilen Bio and Epigenica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Epigenetic biomarkers are discovered and developed via AI platforms.
|
|
| domain | founded_year | HQ Location |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| domain | founded_year | HQ Location |
Proactive healthcare analysis is enabled by DNA-based epigenetic tests.
|
|
| domain | founded_year | HQ Location |
Epigenetic gene silencing technologies are developed for disease treatments.
|
|
| domain | founded_year | HQ Location |
Provider of solutions for the analysis of genomic data
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Chroma Medicine
Frequently Asked Questions about Chroma Medicine
When was Chroma Medicine founded?
Chroma Medicine was founded in 2020.
Where is Chroma Medicine located?
Chroma Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Chroma Medicine?
Catherine Stehman Breen is the current CEO of Chroma Medicine.
Is Chroma Medicine a funded company?
Chroma Medicine is a funded company, having raised a total of $135M across 3 funding rounds to date.
How many employees does Chroma Medicine have?
As of Dec 31, 2023, the latest employee count at Chroma Medicine is 122.
What does Chroma Medicine do?
Chroma Medicine was founded in 2020 and is based in Cambridge, United States. An epigenetic editing platform is developed by the company within the biotechnology sector, focusing on genomic medicines. Gene expression is modulated through precise targeting of the epigenome, without changes to the underlying DNA sequence. This approach is applied to address diseases driven by genetic factors, supporting operations in research and therapeutic development.
Who are the top competitors of Chroma Medicine?
Chroma Medicine's top competitors include FOXO Technologies, Chronomics and Reaction Biology.
What products or services does Chroma Medicine offer?
Chroma Medicine offers Epigenetic Editors, DLVR Particles, and CRMA-1001.
How many acquisitions has Chroma Medicine made?
Chroma Medicine has made 1 acquisition, including Epsilen Bio.
Who are Chroma Medicine's investors?
Chroma Medicine has 18 investors. Key investors include ARE, T. Rowe Price, Janus Henderson Investors, Arch Venture Partners, and Atlas Venture.